Long-Acting Drug Delivery Systems for ART Optimization in Children Living with HIV-1 II (LADDS II) (R61/R33 Clinical Trial Not Allowed)
The goal of this Notice of Funding Opportunity (NOFO) is to support development of LADDS for optimized treatment of HIV-1 in children. This initiative will stimulate the optimization and evaluation of LADDS formulations in suitable preclinical animal models, at an earlier stage of adult drug development. Supporting optimization and evaluation of LADDS formulations in suitable preclinical animal models could accelerate clinical translation in pediatric populations and improve HIV-1 treatment outcomes in children.